SFDA CEO Meets with PMDA and MHLW Leaders in Tokyo to Enhance Medical Collaboration

The Chief Executive Officer of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, met on Tuesday with the Chief Executive of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), Dr. Yasuhiro Fujiwara, and the Councilor for Pharmaceutical Affairs at the Japan's Ministry of Health, Labor, and Welfare (MHLW), Dr. Daisaku Sato. The meeting was held at the MHLW headquarters in Tokyo, Japan, with the attendance of officials from both sides.

The meeting focused on enhancing collaboration in medical products and technology, exploring opportunities for integration within international organizations and forums. This strategic alignment aims to facilitate the exchange of expertise, improve joint coordination in regulatory framework development, and adapt to global advancements in the pharmaceutical and medical device sectors.

The meeting reviewed the progress and accomplishments achieved under the 2020 Memorandum of Cooperation between the SFDA and the MHLW in medical products sector. Key areas of mutual interest included legislation and oversight of bio products, product accessibility, the application of artificial intelligence and data analytics, and collaborative efforts within relevant international bodies.

These engagements underscore the SFDA's commitment to fostering international partnerships and knowledge exchange with leading global regulatory agencies. This initiative aligns with the SFDA's strategic goals of enhancing the quality and safety of medical products and promoting the localization of advanced technologies within the Kingdom of Saudi Arabia. It also supports the objectives of the Health Sector Transformation Program, a key component of Saudi Vision 2030, which seeks to advance the healthcare sector and the pharmaceutical and medical industries.